Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients

Current Medical Research and Opinion

Volumn 30, Issue 7, 2014, Pages 1317-1325

  Laliberté, François ^a   Cloutier, Michel ^a   Nelson, Winnie W ^b   Coleman, Craig I ^c,d   Pilon, Dominic ^a   Olson, William H ^b   Damaraju, C V ^b   Schein, Jeffrey R ^b   Lefebvre, Patrick ^a  

^a Groupe d'analyse   (Canada)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c HARTFORD HOSPITAL   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Comparison of treatment; Nonvalvular atrial fibrillation; Rivaroxaban; Warfarin

Indexed keywords

RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CHADS2 SCORE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROPENSITY SCORE; UNITED STATES; VENOUS THROMBOEMBOLISM; ADOLESCENT; ADULT; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; EVALUATION STUDY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STROKE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COMPARATIVE EFFECTIVENESS RESEARCH; EMBOLISM; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STROKE; THIOPHENES; TREATMENT OUTCOME; WARFARIN; YOUNG ADULT;

EID: 84903592048     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.907140     Document Type: Article

References (19)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 2013;127:e6-245
2. Mantha S, Cabral K, Ansell J. New avenues for anticoagulation in atrial fibrillation. Clin Pharmacol Ther 2013;93:68-77
3. Palareti G, Cosmi B. Bleeding with anticoagulation therapy-who is at risk, and how best to identify such patients. Thromb Haemost 2009;102:268-78
4. Hankey GJ, Eikelboom JW. Novel oral anticoagulants for atrial fibrillation. Curr Atheroscler Rep 2013;15:344
5. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
6. Clayville LR, Anderson KV, Miller SA, et al. New options in anticoagulation for the prevention of venous thromboembolism and stroke. P T 2011;36:86-99
7. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
8. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
9. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
10. Cohen J. Statistical power analysis for the behavioral sciences. Toronto: Academic Press Inc., 1977:19-74
11. Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: A matched analysis using propensity scores. J Clin Epidemiol 2001;54:387-98 (Pubitemid 32303462
12. Austin P. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Comm Stat Simulat Comput 2009;38:1228-34
13. Becattini C, Vedovati MC, Agnelli G. Old and new anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature. Thromb Res 2012;129:392-400
14. Hart RG, Pearce LA, Aguilar MI. Meta-Analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67 (Pubitemid 351650486
15. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:160-98S
16. Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med 2011;171:814-22
17. Laliberté F, Nelson WW, Lefebvre P, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29:675-90
18. Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6:567-74
19. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.